nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—KIT—bone cancer	0.418	0.783	CbGaD
Ponatinib—CYP3A4—bone cancer	0.116	0.217	CbGaD
Ponatinib—ABCB11—Doxorubicin—bone cancer	0.0407	0.231	CbGbCtD
Ponatinib—ABCG2—Carboplatin—bone cancer	0.0337	0.192	CbGbCtD
Ponatinib—ABCG2—Cisplatin—bone cancer	0.0288	0.164	CbGbCtD
Ponatinib—ABCG2—Doxorubicin—bone cancer	0.0193	0.11	CbGbCtD
Ponatinib—ABCG2—Methotrexate—bone cancer	0.0187	0.106	CbGbCtD
Ponatinib—FGFR3—epiphyseal plate—bone cancer	0.012	0.212	CbGeAlD
Ponatinib—ABCB1—Cisplatin—bone cancer	0.0104	0.059	CbGbCtD
Ponatinib—ABCB1—Doxorubicin—bone cancer	0.00697	0.0396	CbGbCtD
Ponatinib—ABCB1—Methotrexate—bone cancer	0.00675	0.0383	CbGbCtD
Ponatinib—CYP2D6—Doxorubicin—bone cancer	0.00657	0.0373	CbGbCtD
Ponatinib—FGFR3—skull—bone cancer	0.00503	0.0886	CbGeAlD
Ponatinib—FGFR3—cartilage tissue—bone cancer	0.00429	0.0755	CbGeAlD
Ponatinib—CYP3A4—Doxorubicin—bone cancer	0.00418	0.0237	CbGbCtD
Ponatinib—FGFR3—appendage—bone cancer	0.00374	0.0658	CbGeAlD
Ponatinib—SRC—periosteum—bone cancer	0.00341	0.0601	CbGeAlD
Ponatinib—FGFR2—skull—bone cancer	0.00329	0.058	CbGeAlD
Ponatinib—KDR—hindlimb—bone cancer	0.00223	0.0394	CbGeAlD
Ponatinib—KDR—appendage—bone cancer	0.00192	0.0338	CbGeAlD
Ponatinib—Nilotinib—BRAF—bone cancer	0.0018	0.347	CrCbGaD
Ponatinib—FGFR4—connective tissue—bone cancer	0.00156	0.0275	CbGeAlD
Ponatinib—Nilotinib—KIT—bone cancer	0.00144	0.279	CrCbGaD
Ponatinib—Imatinib—KIT—bone cancer	0.0012	0.232	CrCbGaD
Ponatinib—LYN—connective tissue—bone cancer	0.00107	0.0189	CbGeAlD
Ponatinib—FGFR3—connective tissue—bone cancer	0.00107	0.0188	CbGeAlD
Ponatinib—FLT3—connective tissue—bone cancer	0.000916	0.0161	CbGeAlD
Ponatinib—RET—connective tissue—bone cancer	0.000735	0.0129	CbGeAlD
Ponatinib—FGFR3—spinal cord—bone cancer	0.000707	0.0125	CbGeAlD
Ponatinib—FGFR2—connective tissue—bone cancer	0.000698	0.0123	CbGeAlD
Ponatinib—TEK—connective tissue—bone cancer	0.000669	0.0118	CbGeAlD
Ponatinib—BCR—tendon—bone cancer	0.000634	0.0112	CbGeAlD
Ponatinib—BCR—bone marrow—bone cancer	0.000615	0.0108	CbGeAlD
Ponatinib—BCR—spinal cord—bone cancer	0.000612	0.0108	CbGeAlD
Ponatinib—FLT3—bone marrow—bone cancer	0.00061	0.0107	CbGeAlD
Ponatinib—PDGFRA—connective tissue—bone cancer	0.000606	0.0107	CbGeAlD
Ponatinib—SRC—connective tissue—bone cancer	0.000595	0.0105	CbGeAlD
Ponatinib—FGFR1—tendon—bone cancer	0.000564	0.00994	CbGeAlD
Ponatinib—KDR—connective tissue—bone cancer	0.000547	0.00964	CbGeAlD
Ponatinib—FGFR1—spinal cord—bone cancer	0.000544	0.00959	CbGeAlD
Ponatinib—ABL1—Doxorubicin—Epirubicin—bone cancer	0.000531	0.173	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Epirubicin—bone cancer	0.000531	0.173	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Epirubicin—bone cancer	0.000531	0.173	CbGdCrCtD
Ponatinib—RET—tendon—bone cancer	0.000505	0.0089	CbGeAlD
Ponatinib—ABL1—Idarubicin—Doxorubicin—bone cancer	0.000491	0.16	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Doxorubicin—bone cancer	0.000491	0.16	CbGdCrCtD
Ponatinib—ABL1—Epirubicin—Doxorubicin—bone cancer	0.000491	0.16	CbGdCrCtD
Ponatinib—LCK—bone marrow—bone cancer	0.000489	0.00862	CbGeAlD
Ponatinib—RET—spinal cord—bone cancer	0.000487	0.00858	CbGeAlD
Ponatinib—KIT—connective tissue—bone cancer	0.000485	0.00854	CbGeAlD
Ponatinib—FGFR2—spinal cord—bone cancer	0.000463	0.00815	CbGeAlD
Ponatinib—TEK—tendon—bone cancer	0.00046	0.0081	CbGeAlD
Ponatinib—TEK—spinal cord—bone cancer	0.000444	0.00782	CbGeAlD
Ponatinib—ABL1—connective tissue—bone cancer	0.000422	0.00743	CbGeAlD
Ponatinib—PDGFRA—tendon—bone cancer	0.000417	0.00734	CbGeAlD
Ponatinib—PDGFRA—spinal cord—bone cancer	0.000402	0.00708	CbGeAlD
Ponatinib—Nilotinib—CYP3A4—bone cancer	0.000399	0.0772	CrCbGaD
Ponatinib—SRC—spinal cord—bone cancer	0.000394	0.00694	CbGeAlD
Ponatinib—KDR—tendon—bone cancer	0.000376	0.00662	CbGeAlD
Ponatinib—KDR—bone marrow—bone cancer	0.000364	0.00642	CbGeAlD
Ponatinib—KDR—spinal cord—bone cancer	0.000363	0.00639	CbGeAlD
Ponatinib—Imatinib—CYP3A4—bone cancer	0.000333	0.0643	CrCbGaD
Ponatinib—KIT—bone marrow—bone cancer	0.000323	0.00568	CbGeAlD
Ponatinib—KIT—spinal cord—bone cancer	0.000321	0.00566	CbGeAlD
Ponatinib—ABL1—tendon—bone cancer	0.00029	0.00511	CbGeAlD
Ponatinib—ABL1—bone marrow—bone cancer	0.000281	0.00495	CbGeAlD
Ponatinib—ABL1—spinal cord—bone cancer	0.00028	0.00493	CbGeAlD
Ponatinib—ABCG2—bone marrow—bone cancer	0.000177	0.00312	CbGeAlD
Ponatinib—Menopausal symptoms—Doxorubicin—bone cancer	0.000177	0.0017	CcSEcCtD
Ponatinib—ABCG2—spinal cord—bone cancer	0.000176	0.00311	CbGeAlD
Ponatinib—Breast disorder—Methotrexate—bone cancer	0.000174	0.00167	CcSEcCtD
Ponatinib—Face oedema—Epirubicin—bone cancer	0.000174	0.00167	CcSEcCtD
Ponatinib—Oedema—Cisplatin—bone cancer	0.000173	0.00165	CcSEcCtD
Ponatinib—Infection—Cisplatin—bone cancer	0.000171	0.00164	CcSEcCtD
Ponatinib—Cardiac failure—Doxorubicin—bone cancer	0.000171	0.00164	CcSEcCtD
Ponatinib—Cerebrovascular accident—Doxorubicin—bone cancer	0.00017	0.00163	CcSEcCtD
Ponatinib—Lethargy—Doxorubicin—bone cancer	0.00017	0.00163	CcSEcCtD
Ponatinib—Nervous system disorder—Cisplatin—bone cancer	0.000169	0.00162	CcSEcCtD
Ponatinib—Thrombocytopenia—Cisplatin—bone cancer	0.000169	0.00162	CcSEcCtD
Ponatinib—Blood creatinine increased—Epirubicin—bone cancer	0.000169	0.00162	CcSEcCtD
Ponatinib—Dehydration—Epirubicin—bone cancer	0.000168	0.00161	CcSEcCtD
Ponatinib—Skin disorder—Cisplatin—bone cancer	0.000168	0.00161	CcSEcCtD
Ponatinib—Hyponatraemia—Doxorubicin—bone cancer	0.000167	0.00161	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000167	0.0016	CcSEcCtD
Ponatinib—Pain in extremity—Doxorubicin—bone cancer	0.000167	0.0016	CcSEcCtD
Ponatinib—Hyperhidrosis—Cisplatin—bone cancer	0.000167	0.0016	CcSEcCtD
Ponatinib—Dry skin—Epirubicin—bone cancer	0.000165	0.00159	CcSEcCtD
Ponatinib—Migraine—Doxorubicin—bone cancer	0.000164	0.00157	CcSEcCtD
Ponatinib—Hypokalaemia—Epirubicin—bone cancer	0.000164	0.00157	CcSEcCtD
Ponatinib—Pancreatitis—Methotrexate—bone cancer	0.000163	0.00157	CcSEcCtD
Ponatinib—Breast disorder—Epirubicin—bone cancer	0.000163	0.00156	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000162	0.00156	CcSEcCtD
Ponatinib—Nasopharyngitis—Epirubicin—bone cancer	0.000161	0.00155	CcSEcCtD
Ponatinib—Face oedema—Doxorubicin—bone cancer	0.000161	0.00154	CcSEcCtD
Ponatinib—Abdominal discomfort—Methotrexate—bone cancer	0.00016	0.00153	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000159	0.00153	CcSEcCtD
Ponatinib—Pancytopenia—Methotrexate—bone cancer	0.000158	0.00152	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000157	0.00151	CcSEcCtD
Ponatinib—Abdominal distension—Epirubicin—bone cancer	0.000157	0.0015	CcSEcCtD
Ponatinib—Blood creatinine increased—Doxorubicin—bone cancer	0.000156	0.0015	CcSEcCtD
Ponatinib—Neutropenia—Methotrexate—bone cancer	0.000156	0.00149	CcSEcCtD
Ponatinib—Dehydration—Doxorubicin—bone cancer	0.000155	0.00149	CcSEcCtD
Ponatinib—Paraesthesia—Cisplatin—bone cancer	0.000155	0.00149	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Methotrexate—bone cancer	0.000155	0.00148	CcSEcCtD
Ponatinib—Dyspnoea—Cisplatin—bone cancer	0.000154	0.00148	CcSEcCtD
Ponatinib—Erectile dysfunction—Methotrexate—bone cancer	0.000153	0.00147	CcSEcCtD
Ponatinib—Dry skin—Doxorubicin—bone cancer	0.000153	0.00147	CcSEcCtD
Ponatinib—Pancreatitis—Epirubicin—bone cancer	0.000153	0.00147	CcSEcCtD
Ponatinib—Hypokalaemia—Doxorubicin—bone cancer	0.000152	0.00146	CcSEcCtD
Ponatinib—Angina pectoris—Epirubicin—bone cancer	0.000152	0.00146	CcSEcCtD
Ponatinib—Breast disorder—Doxorubicin—bone cancer	0.000151	0.00145	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.00015	0.00144	CcSEcCtD
Ponatinib—Decreased appetite—Cisplatin—bone cancer	0.00015	0.00144	CcSEcCtD
Ponatinib—Pneumonia—Methotrexate—bone cancer	0.000149	0.00143	CcSEcCtD
Ponatinib—Nasopharyngitis—Doxorubicin—bone cancer	0.000149	0.00143	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Cisplatin—bone cancer	0.000149	0.00143	CcSEcCtD
Ponatinib—Infestation—Methotrexate—bone cancer	0.000148	0.00142	CcSEcCtD
Ponatinib—Infestation NOS—Methotrexate—bone cancer	0.000148	0.00142	CcSEcCtD
Ponatinib—Pancytopenia—Epirubicin—bone cancer	0.000148	0.00142	CcSEcCtD
Ponatinib—Pain—Cisplatin—bone cancer	0.000148	0.00142	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000147	0.00141	CcSEcCtD
Ponatinib—Neutropenia—Epirubicin—bone cancer	0.000146	0.0014	CcSEcCtD
Ponatinib—Abdominal distension—Doxorubicin—bone cancer	0.000145	0.00139	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Epirubicin—bone cancer	0.000145	0.00139	CcSEcCtD
Ponatinib—Stomatitis—Methotrexate—bone cancer	0.000145	0.00139	CcSEcCtD
Ponatinib—Pancreatitis—Doxorubicin—bone cancer	0.000141	0.00136	CcSEcCtD
Ponatinib—Weight decreased—Epirubicin—bone cancer	0.000141	0.00135	CcSEcCtD
Ponatinib—Hyperglycaemia—Epirubicin—bone cancer	0.000141	0.00135	CcSEcCtD
Ponatinib—Angina pectoris—Doxorubicin—bone cancer	0.00014	0.00135	CcSEcCtD
Ponatinib—Hepatobiliary disease—Methotrexate—bone cancer	0.00014	0.00135	CcSEcCtD
Ponatinib—Epistaxis—Methotrexate—bone cancer	0.00014	0.00134	CcSEcCtD
Ponatinib—Pneumonia—Epirubicin—bone cancer	0.00014	0.00134	CcSEcCtD
Ponatinib—Infestation NOS—Epirubicin—bone cancer	0.000139	0.00133	CcSEcCtD
Ponatinib—Infestation—Epirubicin—bone cancer	0.000139	0.00133	CcSEcCtD
Ponatinib—Pancytopenia—Doxorubicin—bone cancer	0.000137	0.00131	CcSEcCtD
Ponatinib—Body temperature increased—Cisplatin—bone cancer	0.000136	0.00131	CcSEcCtD
Ponatinib—Neuropathy peripheral—Epirubicin—bone cancer	0.000136	0.00131	CcSEcCtD
Ponatinib—Stomatitis—Epirubicin—bone cancer	0.000135	0.0013	CcSEcCtD
Ponatinib—Jaundice—Epirubicin—bone cancer	0.000135	0.0013	CcSEcCtD
Ponatinib—Urinary tract infection—Epirubicin—bone cancer	0.000135	0.0013	CcSEcCtD
Ponatinib—Neutropenia—Doxorubicin—bone cancer	0.000135	0.00129	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000134	0.00129	CcSEcCtD
Ponatinib—Haemoglobin—Methotrexate—bone cancer	0.000134	0.00128	CcSEcCtD
Ponatinib—Haemorrhage—Methotrexate—bone cancer	0.000133	0.00128	CcSEcCtD
Ponatinib—Hepatobiliary disease—Epirubicin—bone cancer	0.000131	0.00126	CcSEcCtD
Ponatinib—Epistaxis—Epirubicin—bone cancer	0.000131	0.00126	CcSEcCtD
Ponatinib—Weight decreased—Doxorubicin—bone cancer	0.00013	0.00125	CcSEcCtD
Ponatinib—Hyperglycaemia—Doxorubicin—bone cancer	0.00013	0.00125	CcSEcCtD
Ponatinib—Pneumonia—Doxorubicin—bone cancer	0.000129	0.00124	CcSEcCtD
Ponatinib—Infestation NOS—Doxorubicin—bone cancer	0.000129	0.00123	CcSEcCtD
Ponatinib—Infestation—Doxorubicin—bone cancer	0.000129	0.00123	CcSEcCtD
Ponatinib—Visual impairment—Methotrexate—bone cancer	0.000128	0.00123	CcSEcCtD
Ponatinib—Neuropathy peripheral—Doxorubicin—bone cancer	0.000126	0.00121	CcSEcCtD
Ponatinib—Haemoglobin—Epirubicin—bone cancer	0.000125	0.0012	CcSEcCtD
Ponatinib—Jaundice—Doxorubicin—bone cancer	0.000125	0.0012	CcSEcCtD
Ponatinib—Stomatitis—Doxorubicin—bone cancer	0.000125	0.0012	CcSEcCtD
Ponatinib—Urinary tract infection—Doxorubicin—bone cancer	0.000125	0.0012	CcSEcCtD
Ponatinib—Haemorrhage—Epirubicin—bone cancer	0.000125	0.0012	CcSEcCtD
Ponatinib—Eye disorder—Methotrexate—bone cancer	0.000125	0.00119	CcSEcCtD
Ponatinib—Hypoaesthesia—Epirubicin—bone cancer	0.000124	0.00119	CcSEcCtD
Ponatinib—Asthenia—Cisplatin—bone cancer	0.000124	0.00119	CcSEcCtD
Ponatinib—Cardiac disorder—Methotrexate—bone cancer	0.000124	0.00119	CcSEcCtD
Ponatinib—Oedema peripheral—Epirubicin—bone cancer	0.000123	0.00118	CcSEcCtD
Ponatinib—Connective tissue disorder—Epirubicin—bone cancer	0.000123	0.00118	CcSEcCtD
Ponatinib—Hepatobiliary disease—Doxorubicin—bone cancer	0.000122	0.00117	CcSEcCtD
Ponatinib—Epistaxis—Doxorubicin—bone cancer	0.000121	0.00116	CcSEcCtD
Ponatinib—Angiopathy—Methotrexate—bone cancer	0.000121	0.00116	CcSEcCtD
Ponatinib—Visual impairment—Epirubicin—bone cancer	0.00012	0.00115	CcSEcCtD
Ponatinib—Mediastinal disorder—Methotrexate—bone cancer	0.00012	0.00115	CcSEcCtD
Ponatinib—Chills—Methotrexate—bone cancer	0.00012	0.00115	CcSEcCtD
Ponatinib—Diarrhoea—Cisplatin—bone cancer	0.000118	0.00113	CcSEcCtD
Ponatinib—Alopecia—Methotrexate—bone cancer	0.000118	0.00113	CcSEcCtD
Ponatinib—Mental disorder—Methotrexate—bone cancer	0.000117	0.00112	CcSEcCtD
Ponatinib—Eye disorder—Epirubicin—bone cancer	0.000117	0.00112	CcSEcCtD
Ponatinib—Malnutrition—Methotrexate—bone cancer	0.000116	0.00111	CcSEcCtD
Ponatinib—Erythema—Methotrexate—bone cancer	0.000116	0.00111	CcSEcCtD
Ponatinib—Haemoglobin—Doxorubicin—bone cancer	0.000116	0.00111	CcSEcCtD
Ponatinib—Flushing—Epirubicin—bone cancer	0.000116	0.00111	CcSEcCtD
Ponatinib—Cardiac disorder—Epirubicin—bone cancer	0.000116	0.00111	CcSEcCtD
Ponatinib—Haemorrhage—Doxorubicin—bone cancer	0.000115	0.00111	CcSEcCtD
Ponatinib—Hypoaesthesia—Doxorubicin—bone cancer	0.000115	0.0011	CcSEcCtD
Ponatinib—Oedema peripheral—Doxorubicin—bone cancer	0.000114	0.00109	CcSEcCtD
Ponatinib—Connective tissue disorder—Doxorubicin—bone cancer	0.000113	0.00109	CcSEcCtD
Ponatinib—Angiopathy—Epirubicin—bone cancer	0.000113	0.00109	CcSEcCtD
Ponatinib—Mediastinal disorder—Epirubicin—bone cancer	0.000112	0.00108	CcSEcCtD
Ponatinib—Back pain—Methotrexate—bone cancer	0.000112	0.00108	CcSEcCtD
Ponatinib—Chills—Epirubicin—bone cancer	0.000112	0.00107	CcSEcCtD
Ponatinib—Arrhythmia—Epirubicin—bone cancer	0.000111	0.00107	CcSEcCtD
Ponatinib—Visual impairment—Doxorubicin—bone cancer	0.000111	0.00107	CcSEcCtD
Ponatinib—Alopecia—Epirubicin—bone cancer	0.00011	0.00106	CcSEcCtD
Ponatinib—Vomiting—Cisplatin—bone cancer	0.00011	0.00105	CcSEcCtD
Ponatinib—Vision blurred—Methotrexate—bone cancer	0.000109	0.00105	CcSEcCtD
Ponatinib—Mental disorder—Epirubicin—bone cancer	0.000109	0.00105	CcSEcCtD
Ponatinib—Rash—Cisplatin—bone cancer	0.000109	0.00104	CcSEcCtD
Ponatinib—Dermatitis—Cisplatin—bone cancer	0.000109	0.00104	CcSEcCtD
Ponatinib—Malnutrition—Epirubicin—bone cancer	0.000109	0.00104	CcSEcCtD
Ponatinib—Erythema—Epirubicin—bone cancer	0.000109	0.00104	CcSEcCtD
Ponatinib—Eye disorder—Doxorubicin—bone cancer	0.000108	0.00103	CcSEcCtD
Ponatinib—Anaemia—Methotrexate—bone cancer	0.000107	0.00103	CcSEcCtD
Ponatinib—Cardiac disorder—Doxorubicin—bone cancer	0.000107	0.00103	CcSEcCtD
Ponatinib—Flushing—Doxorubicin—bone cancer	0.000107	0.00103	CcSEcCtD
Ponatinib—Back pain—Epirubicin—bone cancer	0.000105	0.00101	CcSEcCtD
Ponatinib—Angiopathy—Doxorubicin—bone cancer	0.000105	0.001	CcSEcCtD
Ponatinib—Muscle spasms—Epirubicin—bone cancer	0.000104	0.001	CcSEcCtD
Ponatinib—Mediastinal disorder—Doxorubicin—bone cancer	0.000104	0.000998	CcSEcCtD
Ponatinib—Leukopenia—Methotrexate—bone cancer	0.000104	0.000996	CcSEcCtD
Ponatinib—Chills—Doxorubicin—bone cancer	0.000104	0.000993	CcSEcCtD
Ponatinib—Arrhythmia—Doxorubicin—bone cancer	0.000103	0.000989	CcSEcCtD
Ponatinib—Nausea—Cisplatin—bone cancer	0.000102	0.000983	CcSEcCtD
Ponatinib—Vision blurred—Epirubicin—bone cancer	0.000102	0.000981	CcSEcCtD
Ponatinib—Alopecia—Doxorubicin—bone cancer	0.000102	0.000978	CcSEcCtD
Ponatinib—Cough—Methotrexate—bone cancer	0.000101	0.000971	CcSEcCtD
Ponatinib—Mental disorder—Doxorubicin—bone cancer	0.000101	0.00097	CcSEcCtD
Ponatinib—Malnutrition—Doxorubicin—bone cancer	0.0001	0.000964	CcSEcCtD
Ponatinib—Erythema—Doxorubicin—bone cancer	0.0001	0.000964	CcSEcCtD
Ponatinib—Anaemia—Epirubicin—bone cancer	0.0001	0.000963	CcSEcCtD
Ponatinib—Arthralgia—Methotrexate—bone cancer	9.88e-05	0.000947	CcSEcCtD
Ponatinib—Myalgia—Methotrexate—bone cancer	9.88e-05	0.000947	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	9.81e-05	0.000941	CcSEcCtD
Ponatinib—Leukopenia—Epirubicin—bone cancer	9.72e-05	0.000932	CcSEcCtD
Ponatinib—Back pain—Doxorubicin—bone cancer	9.72e-05	0.000932	CcSEcCtD
Ponatinib—Muscle spasms—Doxorubicin—bone cancer	9.66e-05	0.000926	CcSEcCtD
Ponatinib—Cough—Epirubicin—bone cancer	9.47e-05	0.000909	CcSEcCtD
Ponatinib—Vision blurred—Doxorubicin—bone cancer	9.47e-05	0.000908	CcSEcCtD
Ponatinib—Infection—Methotrexate—bone cancer	9.4e-05	0.000902	CcSEcCtD
Ponatinib—Hypertension—Epirubicin—bone cancer	9.37e-05	0.000899	CcSEcCtD
Ponatinib—Nervous system disorder—Methotrexate—bone cancer	9.28e-05	0.000891	CcSEcCtD
Ponatinib—Anaemia—Doxorubicin—bone cancer	9.28e-05	0.000891	CcSEcCtD
Ponatinib—Thrombocytopenia—Methotrexate—bone cancer	9.27e-05	0.000889	CcSEcCtD
Ponatinib—Arthralgia—Epirubicin—bone cancer	9.24e-05	0.000887	CcSEcCtD
Ponatinib—Myalgia—Epirubicin—bone cancer	9.24e-05	0.000887	CcSEcCtD
Ponatinib—Skin disorder—Methotrexate—bone cancer	9.2e-05	0.000882	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	9.18e-05	0.00088	CcSEcCtD
Ponatinib—Hyperhidrosis—Methotrexate—bone cancer	9.15e-05	0.000878	CcSEcCtD
Ponatinib—Dry mouth—Epirubicin—bone cancer	9.04e-05	0.000867	CcSEcCtD
Ponatinib—Leukopenia—Doxorubicin—bone cancer	8.99e-05	0.000862	CcSEcCtD
Ponatinib—Oedema—Epirubicin—bone cancer	8.86e-05	0.00085	CcSEcCtD
Ponatinib—Infection—Epirubicin—bone cancer	8.8e-05	0.000844	CcSEcCtD
Ponatinib—Cough—Doxorubicin—bone cancer	8.76e-05	0.000841	CcSEcCtD
Ponatinib—ABCB1—bone marrow—bone cancer	8.74e-05	0.00154	CbGeAlD
Ponatinib—ABCB1—spinal cord—bone cancer	8.7e-05	0.00153	CbGeAlD
Ponatinib—Nervous system disorder—Epirubicin—bone cancer	8.69e-05	0.000833	CcSEcCtD
Ponatinib—Thrombocytopenia—Epirubicin—bone cancer	8.67e-05	0.000832	CcSEcCtD
Ponatinib—Hypertension—Doxorubicin—bone cancer	8.67e-05	0.000832	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Methotrexate—bone cancer	8.62e-05	0.000827	CcSEcCtD
Ponatinib—Skin disorder—Epirubicin—bone cancer	8.61e-05	0.000826	CcSEcCtD
Ponatinib—Hyperhidrosis—Epirubicin—bone cancer	8.56e-05	0.000822	CcSEcCtD
Ponatinib—Insomnia—Methotrexate—bone cancer	8.56e-05	0.000821	CcSEcCtD
Ponatinib—Arthralgia—Doxorubicin—bone cancer	8.55e-05	0.00082	CcSEcCtD
Ponatinib—Myalgia—Doxorubicin—bone cancer	8.55e-05	0.00082	CcSEcCtD
Ponatinib—Paraesthesia—Methotrexate—bone cancer	8.5e-05	0.000815	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	8.49e-05	0.000815	CcSEcCtD
Ponatinib—Dyspnoea—Methotrexate—bone cancer	8.44e-05	0.00081	CcSEcCtD
Ponatinib—Dry mouth—Doxorubicin—bone cancer	8.36e-05	0.000802	CcSEcCtD
Ponatinib—Dyspepsia—Methotrexate—bone cancer	8.33e-05	0.000799	CcSEcCtD
Ponatinib—Decreased appetite—Methotrexate—bone cancer	8.23e-05	0.000789	CcSEcCtD
Ponatinib—Oedema—Doxorubicin—bone cancer	8.2e-05	0.000786	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Methotrexate—bone cancer	8.17e-05	0.000784	CcSEcCtD
Ponatinib—Fatigue—Methotrexate—bone cancer	8.16e-05	0.000783	CcSEcCtD
Ponatinib—Infection—Doxorubicin—bone cancer	8.14e-05	0.000781	CcSEcCtD
Ponatinib—Pain—Methotrexate—bone cancer	8.1e-05	0.000777	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Epirubicin—bone cancer	8.07e-05	0.000774	CcSEcCtD
Ponatinib—Nervous system disorder—Doxorubicin—bone cancer	8.04e-05	0.000771	CcSEcCtD
Ponatinib—Thrombocytopenia—Doxorubicin—bone cancer	8.03e-05	0.00077	CcSEcCtD
Ponatinib—Insomnia—Epirubicin—bone cancer	8.01e-05	0.000769	CcSEcCtD
Ponatinib—Skin disorder—Doxorubicin—bone cancer	7.96e-05	0.000764	CcSEcCtD
Ponatinib—Paraesthesia—Epirubicin—bone cancer	7.96e-05	0.000763	CcSEcCtD
Ponatinib—Hyperhidrosis—Doxorubicin—bone cancer	7.92e-05	0.00076	CcSEcCtD
Ponatinib—Dyspnoea—Epirubicin—bone cancer	7.9e-05	0.000758	CcSEcCtD
Ponatinib—Dyspepsia—Epirubicin—bone cancer	7.8e-05	0.000748	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methotrexate—bone cancer	7.74e-05	0.000743	CcSEcCtD
Ponatinib—Decreased appetite—Epirubicin—bone cancer	7.7e-05	0.000739	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Epirubicin—bone cancer	7.65e-05	0.000734	CcSEcCtD
Ponatinib—Fatigue—Epirubicin—bone cancer	7.64e-05	0.000733	CcSEcCtD
Ponatinib—Pain—Epirubicin—bone cancer	7.58e-05	0.000727	CcSEcCtD
Ponatinib—Constipation—Epirubicin—bone cancer	7.58e-05	0.000727	CcSEcCtD
Ponatinib—Abdominal pain—Methotrexate—bone cancer	7.48e-05	0.000718	CcSEcCtD
Ponatinib—Body temperature increased—Methotrexate—bone cancer	7.48e-05	0.000718	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Doxorubicin—bone cancer	7.47e-05	0.000716	CcSEcCtD
Ponatinib—Insomnia—Doxorubicin—bone cancer	7.41e-05	0.000711	CcSEcCtD
Ponatinib—Paraesthesia—Doxorubicin—bone cancer	7.36e-05	0.000706	CcSEcCtD
Ponatinib—Dyspnoea—Doxorubicin—bone cancer	7.31e-05	0.000701	CcSEcCtD
Ponatinib—Gastrointestinal pain—Epirubicin—bone cancer	7.24e-05	0.000695	CcSEcCtD
Ponatinib—Dyspepsia—Doxorubicin—bone cancer	7.22e-05	0.000692	CcSEcCtD
Ponatinib—Decreased appetite—Doxorubicin—bone cancer	7.13e-05	0.000684	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Doxorubicin—bone cancer	7.08e-05	0.000679	CcSEcCtD
Ponatinib—Fatigue—Doxorubicin—bone cancer	7.07e-05	0.000678	CcSEcCtD
Ponatinib—Pain—Doxorubicin—bone cancer	7.01e-05	0.000672	CcSEcCtD
Ponatinib—Constipation—Doxorubicin—bone cancer	7.01e-05	0.000672	CcSEcCtD
Ponatinib—Body temperature increased—Epirubicin—bone cancer	7e-05	0.000672	CcSEcCtD
Ponatinib—Abdominal pain—Epirubicin—bone cancer	7e-05	0.000672	CcSEcCtD
Ponatinib—Asthenia—Methotrexate—bone cancer	6.79e-05	0.000652	CcSEcCtD
Ponatinib—Gastrointestinal pain—Doxorubicin—bone cancer	6.7e-05	0.000643	CcSEcCtD
Ponatinib—Pruritus—Methotrexate—bone cancer	6.7e-05	0.000643	CcSEcCtD
Ponatinib—Abdominal pain—Doxorubicin—bone cancer	6.48e-05	0.000622	CcSEcCtD
Ponatinib—Body temperature increased—Doxorubicin—bone cancer	6.48e-05	0.000622	CcSEcCtD
Ponatinib—Diarrhoea—Methotrexate—bone cancer	6.48e-05	0.000621	CcSEcCtD
Ponatinib—Asthenia—Epirubicin—bone cancer	6.36e-05	0.00061	CcSEcCtD
Ponatinib—Pruritus—Epirubicin—bone cancer	6.27e-05	0.000601	CcSEcCtD
Ponatinib—Dizziness—Methotrexate—bone cancer	6.26e-05	0.000601	CcSEcCtD
Ponatinib—Diarrhoea—Epirubicin—bone cancer	6.06e-05	0.000582	CcSEcCtD
Ponatinib—Vomiting—Methotrexate—bone cancer	6.02e-05	0.000577	CcSEcCtD
Ponatinib—Rash—Methotrexate—bone cancer	5.97e-05	0.000573	CcSEcCtD
Ponatinib—Dermatitis—Methotrexate—bone cancer	5.96e-05	0.000572	CcSEcCtD
Ponatinib—Headache—Methotrexate—bone cancer	5.93e-05	0.000569	CcSEcCtD
Ponatinib—Asthenia—Doxorubicin—bone cancer	5.88e-05	0.000564	CcSEcCtD
Ponatinib—Dizziness—Epirubicin—bone cancer	5.86e-05	0.000562	CcSEcCtD
Ponatinib—Pruritus—Doxorubicin—bone cancer	5.8e-05	0.000556	CcSEcCtD
Ponatinib—Vomiting—Epirubicin—bone cancer	5.63e-05	0.00054	CcSEcCtD
Ponatinib—Nausea—Methotrexate—bone cancer	5.62e-05	0.000539	CcSEcCtD
Ponatinib—Diarrhoea—Doxorubicin—bone cancer	5.61e-05	0.000538	CcSEcCtD
Ponatinib—Rash—Epirubicin—bone cancer	5.59e-05	0.000536	CcSEcCtD
Ponatinib—Dermatitis—Epirubicin—bone cancer	5.58e-05	0.000535	CcSEcCtD
Ponatinib—Headache—Epirubicin—bone cancer	5.55e-05	0.000532	CcSEcCtD
Ponatinib—Dizziness—Doxorubicin—bone cancer	5.42e-05	0.00052	CcSEcCtD
Ponatinib—Nausea—Epirubicin—bone cancer	5.26e-05	0.000505	CcSEcCtD
Ponatinib—Vomiting—Doxorubicin—bone cancer	5.21e-05	0.0005	CcSEcCtD
Ponatinib—Rash—Doxorubicin—bone cancer	5.17e-05	0.000496	CcSEcCtD
Ponatinib—Dermatitis—Doxorubicin—bone cancer	5.16e-05	0.000495	CcSEcCtD
Ponatinib—Headache—Doxorubicin—bone cancer	5.14e-05	0.000493	CcSEcCtD
Ponatinib—Nausea—Doxorubicin—bone cancer	4.87e-05	0.000467	CcSEcCtD
Ponatinib—LYN—Adaptive Immune System—MDM2—bone cancer	1.37e-05	0.000113	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—MMP9—bone cancer	1.37e-05	0.000113	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ATF1—bone cancer	1.36e-05	0.000112	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—EGFR—bone cancer	1.36e-05	0.000112	CbGpPWpGaD
Ponatinib—FGFR3—Disease—MDM2—bone cancer	1.36e-05	0.000112	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—MMP9—bone cancer	1.36e-05	0.000112	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ATF1—bone cancer	1.36e-05	0.000112	CbGpPWpGaD
Ponatinib—SRC—Immune System—ATF1—bone cancer	1.34e-05	0.000111	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL3—bone cancer	1.33e-05	0.00011	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL3—bone cancer	1.32e-05	0.000109	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—MMP2—bone cancer	1.32e-05	0.000109	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—KIT—bone cancer	1.31e-05	0.000108	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL3—bone cancer	1.31e-05	0.000108	CbGpPWpGaD
Ponatinib—FGFR3—Disease—PTGS2—bone cancer	1.31e-05	0.000108	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—DHFR—bone cancer	1.31e-05	0.000108	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NDUFA12—bone cancer	1.3e-05	0.000107	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—GNA11—bone cancer	1.29e-05	0.000106	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.29e-05	0.000106	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—MDM2—bone cancer	1.29e-05	0.000106	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—KIT—bone cancer	1.29e-05	0.000106	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—JUN—bone cancer	1.28e-05	0.000106	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—KIT—bone cancer	1.26e-05	0.000104	CbGpPWpGaD
Ponatinib—FGFR4—Disease—EGFR—bone cancer	1.26e-05	0.000104	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—EGFR—bone cancer	1.25e-05	0.000103	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—EGFR—bone cancer	1.25e-05	0.000103	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—EGFR—bone cancer	1.24e-05	0.000102	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—JUN—bone cancer	1.24e-05	0.000102	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—JUN—bone cancer	1.23e-05	0.000102	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—GNA11—bone cancer	1.22e-05	0.000101	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TGFBR2—bone cancer	1.22e-05	0.0001	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—KIT—bone cancer	1.21e-05	9.97e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—KIT—bone cancer	1.2e-05	9.89e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ATF1—bone cancer	1.2e-05	9.88e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TGFBR2—bone cancer	1.2e-05	9.87e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—KIT—bone cancer	1.2e-05	9.86e-05	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—EGFR—bone cancer	1.19e-05	9.8e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—KIT—bone cancer	1.19e-05	9.79e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—TGFBR2—bone cancer	1.17e-05	9.65e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—MDM2—bone cancer	1.17e-05	9.64e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL3—bone cancer	1.17e-05	9.64e-05	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—EGFR—bone cancer	1.17e-05	9.63e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SMO—bone cancer	1.15e-05	9.52e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IGF1R—bone cancer	1.15e-05	9.45e-05	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—EGFR—bone cancer	1.14e-05	9.41e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—BRAF—bone cancer	1.14e-05	9.37e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TGFBR2—bone cancer	1.14e-05	9.37e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TGFBR2—bone cancer	1.13e-05	9.34e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IGF1R—bone cancer	1.13e-05	9.29e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—MDM2—bone cancer	1.12e-05	9.26e-05	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—EGFR—bone cancer	1.12e-05	9.25e-05	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—EGFR—bone cancer	1.12e-05	9.24e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—JUN—bone cancer	1.12e-05	9.23e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—BRAF—bone cancer	1.12e-05	9.2e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—CYP3A4—bone cancer	1.11e-05	9.15e-05	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—EGFR—bone cancer	1.11e-05	9.13e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—KIT—bone cancer	1.11e-05	9.13e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—EGFR—bone cancer	1.1e-05	9.11e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—KIT—bone cancer	1.1e-05	9.1e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—EGFR—bone cancer	1.1e-05	9.1e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—EGFR—bone cancer	1.1e-05	9.06e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—BRAF—bone cancer	1.1e-05	9.04e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—MMP9—bone cancer	1.09e-05	8.98e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NT5C3A—bone cancer	1.07e-05	8.85e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IGF1R—bone cancer	1.07e-05	8.81e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IGF1R—bone cancer	1.07e-05	8.79e-05	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—EGFR—bone cancer	1.06e-05	8.77e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—EGFR—bone cancer	1.06e-05	8.75e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—GNA11—bone cancer	1.06e-05	8.71e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—KIT—bone cancer	1.05e-05	8.7e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—KIT—bone cancer	1.05e-05	8.69e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—KIT—bone cancer	1.05e-05	8.66e-05	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—TP53—bone cancer	1.05e-05	8.64e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—BRAF—bone cancer	1.04e-05	8.58e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—BRAF—bone cancer	1.04e-05	8.56e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—TGFBR2—bone cancer	1.04e-05	8.54e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—MDM2—bone cancer	1.03e-05	8.53e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SMO—bone cancer	1.02e-05	8.43e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—JUN—bone cancer	1.02e-05	8.38e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.01e-05	8.35e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—MDM2—bone cancer	1.01e-05	8.35e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ENO2—bone cancer	1.01e-05	8.34e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—EGFR—bone cancer	1.01e-05	8.3e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TGFBR2—bone cancer	9.99e-06	8.24e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—MDM2—bone cancer	9.95e-06	8.2e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—MDM2—bone cancer	9.94e-06	8.19e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—MMP9—bone cancer	9.91e-06	8.17e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—BRAF—bone cancer	9.9e-06	8.16e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ATF1—bone cancer	9.82e-06	8.1e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—EGFR—bone cancer	9.74e-06	8.04e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—EGFR—bone cancer	9.7e-06	8e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL3—bone cancer	9.58e-06	7.9e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MDM2—bone cancer	9.52e-06	7.85e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—GSTP1—bone cancer	9.49e-06	7.83e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—MDM2—bone cancer	9.44e-06	7.79e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—MDM2—bone cancer	9.42e-06	7.77e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IGF1R—bone cancer	9.4e-06	7.75e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—DHFR—bone cancer	9.38e-06	7.74e-05	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—EGFR—bone cancer	9.36e-06	7.72e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—MDM2—bone cancer	9.35e-06	7.71e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—GNA11—bone cancer	9.35e-06	7.71e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—EGFR—bone cancer	9.29e-06	7.66e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—MDM2—bone cancer	9.18e-06	7.57e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—TP53—bone cancer	9.09e-06	7.49e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—TP53—bone cancer	9.05e-06	7.46e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—PTGS2—bone cancer	9.01e-06	7.43e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—JUN—bone cancer	8.99e-06	7.42e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—PTGS2—bone cancer	8.85e-06	7.3e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—JUN—bone cancer	8.8e-06	7.26e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—EGFR—bone cancer	8.8e-06	7.25e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GNA11—bone cancer	8.77e-06	7.23e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ENO2—bone cancer	8.76e-06	7.22e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—MDM2—bone cancer	8.72e-06	7.19e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—MDM2—bone cancer	8.69e-06	7.17e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ATF1—bone cancer	8.69e-06	7.17e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—JUN—bone cancer	8.65e-06	7.13e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—KIT—bone cancer	8.64e-06	7.13e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	8.51e-06	7.02e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL3—bone cancer	8.48e-06	6.99e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—PTGS2—bone cancer	8.4e-06	6.93e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—PTGS2—bone cancer	8.38e-06	6.91e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KIT—bone cancer	8.31e-06	6.86e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—MDM2—bone cancer	8.31e-06	6.85e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MDM2—bone cancer	8.29e-06	6.84e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—JUN—bone cancer	8.28e-06	6.83e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—MDM2—bone cancer	8.27e-06	6.82e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—JUN—bone cancer	8.21e-06	6.77e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TGFBR2—bone cancer	8.19e-06	6.75e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—JUN—bone cancer	8.18e-06	6.75e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—DHFR—bone cancer	8.13e-06	6.7e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MMP9—bone cancer	8.05e-06	6.64e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—EGFR—bone cancer	8.01e-06	6.6e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—EGFR—bone cancer	7.99e-06	6.59e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—KIT—bone cancer	7.98e-06	6.58e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CYP3A4—bone cancer	7.95e-06	6.56e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—BRAF—bone cancer	7.82e-06	6.45e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KIT—bone cancer	7.75e-06	6.39e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KIT—bone cancer	7.73e-06	6.37e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IGF1R—bone cancer	7.71e-06	6.35e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—BRAF—bone cancer	7.68e-06	6.33e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—EGFR—bone cancer	7.67e-06	6.33e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—KIT—bone cancer	7.65e-06	6.31e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ENO2—bone cancer	7.63e-06	6.29e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GNA11—bone cancer	7.59e-06	6.26e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—BRAF—bone cancer	7.5e-06	6.19e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TP53—bone cancer	7.45e-06	6.14e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PTGS2—bone cancer	7.44e-06	6.13e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TP53—bone cancer	7.39e-06	6.09e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—BRAF—bone cancer	7.28e-06	6.01e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—BRAF—bone cancer	7.27e-06	5.99e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TGFBR2—bone cancer	7.25e-06	5.98e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—JUN—bone cancer	7.22e-06	5.95e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—JUN—bone cancer	7.21e-06	5.95e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ENO2—bone cancer	7.19e-06	5.93e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—JUN—bone cancer	7.19e-06	5.93e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—DHFR—bone cancer	7.08e-06	5.84e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—EGFR—bone cancer	7.07e-06	5.83e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—KIT—bone cancer	7.06e-06	5.83e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MMP9—bone cancer	7.01e-06	5.78e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—EGFR—bone cancer	6.92e-06	5.71e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CYP3A4—bone cancer	6.88e-06	5.68e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.85e-06	5.65e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IGF1R—bone cancer	6.82e-06	5.63e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KIT—bone cancer	6.82e-06	5.62e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—MDM2—bone cancer	6.81e-06	5.61e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GSTP1—bone cancer	6.8e-06	5.61e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—EGFR—bone cancer	6.8e-06	5.61e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—EGFR—bone cancer	6.79e-06	5.6e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—DHFR—bone cancer	6.67e-06	5.5e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—BRAF—bone cancer	6.64e-06	5.48e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GNA11—bone cancer	6.62e-06	5.46e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TP53—bone cancer	6.59e-06	5.44e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MDM2—bone cancer	6.55e-06	5.4e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—EGFR—bone cancer	6.51e-06	5.37e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—EGFR—bone cancer	6.45e-06	5.32e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—EGFR—bone cancer	6.43e-06	5.31e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MDM2—bone cancer	6.43e-06	5.3e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—BRAF—bone cancer	6.41e-06	5.29e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—EGFR—bone cancer	6.39e-06	5.27e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MDM2—bone cancer	6.29e-06	5.18e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—EGFR—bone cancer	6.28e-06	5.18e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GNA11—bone cancer	6.23e-06	5.14e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MDM2—bone cancer	6.1e-06	5.03e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MDM2—bone cancer	6.09e-06	5.02e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTGS2—bone cancer	6.06e-06	5e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—MDM2—bone cancer	6.03e-06	4.97e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP3A4—bone cancer	6e-06	4.95e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—EGFR—bone cancer	5.96e-06	4.91e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—EGFR—bone cancer	5.94e-06	4.9e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—JUN—bone cancer	5.92e-06	4.88e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GSTP1—bone cancer	5.89e-06	4.86e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—JUN—bone cancer	5.69e-06	4.69e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—EGFR—bone cancer	5.68e-06	4.68e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—EGFR—bone cancer	5.67e-06	4.67e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP3A4—bone cancer	5.65e-06	4.66e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—EGFR—bone cancer	5.65e-06	4.66e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—JUN—bone cancer	5.59e-06	4.61e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KIT—bone cancer	5.59e-06	4.61e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MDM2—bone cancer	5.56e-06	4.59e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MMP9—bone cancer	5.54e-06	4.57e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—bone cancer	5.46e-06	4.51e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MMP9—bone cancer	5.44e-06	4.49e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MDM2—bone cancer	5.37e-06	4.43e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTGS2—bone cancer	5.36e-06	4.42e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—JUN—bone cancer	5.31e-06	4.38e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—JUN—bone cancer	5.29e-06	4.36e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—BRAF—bone cancer	5.25e-06	4.33e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—JUN—bone cancer	5.24e-06	4.32e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MMP9—bone cancer	5.16e-06	4.26e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MMP9—bone cancer	5.15e-06	4.25e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTP1—bone cancer	5.13e-06	4.23e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KIT—bone cancer	4.95e-06	4.08e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—bone cancer	4.92e-06	4.05e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTP1—bone cancer	4.83e-06	3.99e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—bone cancer	4.76e-06	3.92e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ENO2—bone cancer	4.7e-06	3.88e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—JUN—bone cancer	4.67e-06	3.85e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—EGFR—bone cancer	4.65e-06	3.84e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—BRAF—bone cancer	4.65e-06	3.84e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—bone cancer	4.54e-06	3.74e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—bone cancer	4.47e-06	3.69e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MDM2—bone cancer	4.4e-06	3.63e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—bone cancer	4.39e-06	3.62e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—DHFR—bone cancer	4.36e-06	3.6e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—bone cancer	4.3e-06	3.54e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—bone cancer	4.17e-06	3.44e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—bone cancer	4.16e-06	3.43e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—bone cancer	4.12e-06	3.4e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GNA11—bone cancer	4.08e-06	3.36e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MDM2—bone cancer	3.9e-06	3.21e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—JUN—bone cancer	3.83e-06	3.16e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—bone cancer	3.8e-06	3.14e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—bone cancer	3.76e-06	3.1e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—bone cancer	3.72e-06	3.07e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—bone cancer	3.69e-06	3.04e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—bone cancer	3.67e-06	3.03e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—bone cancer	3.52e-06	2.9e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—bone cancer	3.5e-06	2.89e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—bone cancer	3.49e-06	2.88e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—JUN—bone cancer	3.39e-06	2.79e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—bone cancer	3.3e-06	2.72e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTP1—bone cancer	3.16e-06	2.61e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—bone cancer	3.08e-06	2.54e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—bone cancer	3.05e-06	2.52e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—bone cancer	3.01e-06	2.48e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—bone cancer	2.66e-06	2.2e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—bone cancer	2.66e-06	2.19e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—bone cancer	2.53e-06	2.08e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—bone cancer	2.5e-06	2.07e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—bone cancer	2.24e-06	1.84e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—bone cancer	1.64e-06	1.35e-05	CbGpPWpGaD
